Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 211,901,584
  • Shares Outstanding, K 5,534,123
  • Annual Sales, $ 53,647 M
  • Annual Income, $ 11,152 M
  • 60-Month Beta 0.66
  • Price/Sales 3.92
  • Price/Cash Flow 9.03
  • Price/Book 3.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.57
  • Number of Estimates 3
  • High Estimate 0.59
  • Low Estimate 0.55
  • Prior Year 0.64
  • Growth Rate Est. (year over year) -10.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.30 +5.48%
on 11/13/19
38.88 -1.52%
on 11/29/19
+0.68 (+1.81%)
since 11/06/19
3-Month
34.60 +10.66%
on 10/03/19
38.94 -1.67%
on 11/01/19
+1.79 (+4.90%)
since 09/06/19
52-Week
33.97 +12.72%
on 08/15/19
44.94 -14.81%
on 12/07/18
-6.69 (-14.87%)
since 12/06/18

Most Recent Stories

More News
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating investigational SB-525...

SGMO : 11.66 (+0.56%)
PFE : 38.29 (+0.68%)
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ

The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.

GSK : 45.51 (+0.66%)
AZN : 47.68 (+0.13%)
MRK : 88.85 (+0.11%)
PFE : 38.29 (+0.68%)
RHHBY : 38.5700 (+0.36%)
JNJ : 140.38 (+0.59%)
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV

Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.

GSK : 45.51 (+0.66%)
PFE : 38.29 (+0.68%)
JNJ : 140.38 (+0.59%)
GILD : 67.08 (+1.74%)
Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD

The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.

GSK : 45.51 (+0.66%)
MRK : 88.85 (+0.11%)
PFE : 38.29 (+0.68%)
BMY : 59.95 (+0.79%)
Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised)

Pfizer (PFE)/Astellas' Xtandi gets approval in China to treat metastatic castration-resistant prostate cancer (CRPC).

BMY : 59.95 (+0.79%)
MRK : 88.85 (+0.11%)
RHHBY : 38.5700 (+0.36%)
PFE : 38.29 (+0.68%)
After Yesterday's Decline of 1.10%, Pfizer Inc Offers Investors Better Value

Pfizer Inc (NYSE:PFE) traded in a range yesterday that spanned from a low of $37.84 to a high of $38.05. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $38.25 on...

PFE : 38.29 (+0.68%)
Pfizer Inc Falls 1.10% on Heavy Volume: Watch For Potential Rebound

Pfizer Inc (NYSE:PFE) traded in a range yesterday that spanned from a low of $37.84 to a high of $38.05. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $38.25 on...

PFE : 38.29 (+0.68%)
Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US

Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

RHHBY : 38.5700 (+0.36%)
PFE : 38.29 (+0.68%)
TEVA : 9.92 (+1.02%)
MYL : 19.29 (+2.06%)
Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer

Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.

GSK : 45.51 (+0.66%)
PFE : 38.29 (+0.68%)
MRK : 88.85 (+0.11%)
AMGN : 233.77 (+0.15%)
NavaDerm Partners adds Dan Wechsler as Executive Chairman

NavaDerm Partners ("NavaDerm" or the "Company"), a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners ("BelHealth"), a New York-based healthcare private...

MLNT : 1.74 (+9.43%)
MRK : 88.85 (+0.11%)
PFE : 38.29 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade PFE with:

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 38.65
1st Resistance Point 38.47
Last Price 38.29
1st Support Level 38.16
2nd Support Level 38.04

See More

52-Week High 44.94
Fibonacci 61.8% 40.75
Fibonacci 50% 39.46
Last Price 38.29
Fibonacci 38.2% 38.16
52-Week Low 33.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar